Patients with multiple sclerosis found that their symptoms did not worsen with intake of tolebrutinib, in the GEMINI 1 and 2 studies.
But tolebrutinib showed something novel at ECTRIMS. In the phase III HERCULES trial, tolebrutinib slowed confirmed disability ...
But because we don’t know what’s driving it, we don’t know what to go after.” The study was supported by Sanofi. Cree is a co ...
Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...
Sanofi lifts lid on MS data behind tolebrutinib’s mixed phase 3 scorecard, plans ‘24 approval filings Rilzabrutinib is an oral inhibitor of Bruton’s tyrosine kinase (BTK), a protein that ...
Sanofi is still plugging away with its oral BTK inhibitor tolebrutinib in multiple sclerosis, but has decided to abandon efforts to develop the drug for neuromuscular disorder myasthenia gravis.
Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...
People with multiple sclerosis (MS) often stop taking disease-modifying therapy as they transition from relapsing-remitting MS to secondary progressive MS. This study shows that people who stop stop ...
The move comes just before a Biden administration deadline for Israel to deliver more aid to the enclave or risk a cutoff of military supplies. By Hiba Yazbek A day after the prime minister of ...
Nov. 6, 2024 — Researchers have developed AI-driven mobile robots that can carry out chemical synthesis research with extraordinary efficiency. Researchers show how mobile robots that use AI ...
Nov. 11, 2024 — Asthma is associated with memory difficulties in children, and early onset of asthma may exacerbate memory deficits, according to a new ... Swirling Polar Vortices Likely Exist ...
OFF THE RECORD: Four cameras on the coast guard vessel were removed in 2022 amid a campaign to phase out the use of Chinese products, an investigation found ...